271 related articles for article (PubMed ID: 24033728)
1. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
2. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.
Damkier P
Br J Clin Pharmacol; 2014 Aug; 78(2):431-2. PubMed ID: 24446761
[No Abstract] [Full Text] [Related]
6. CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Aug; 78(2):433-4. PubMed ID: 24446792
[No Abstract] [Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
[No Abstract] [Full Text] [Related]
10. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC;
Breast Cancer Res Treat; 2019 Feb; 173(3):521-532. PubMed ID: 30411242
[TBL] [Abstract][Full Text] [Related]
19. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
